M
Michael Aviram
Researcher at Technion – Israel Institute of Technology
Publications - 489
Citations - 32705
Michael Aviram is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Cholesterol & Lipoprotein. The author has an hindex of 94, co-authored 479 publications receiving 31141 citations. Previous affiliations of Michael Aviram include University of Tromsø & Steward Health Care System.
Papers
More filters
Journal ArticleDOI
Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated.
Michael Aviram,Irit Maor,Shlomo Keidar,Tony Hayek,J. Oiknine,Yaron Bar-El,Zvi Adler,Victor Kertzman,Simcha Milo +8 more
TL;DR: Both oxidation and aggregation of lesioned LDL could be the result of aortic lesioned-induced modification of the lipoprotein, and both of these modified forms of LDL can further contribute to the acceleration of the atherosclerotic process.
Journal ArticleDOI
Pomegranate juice sugar fraction reduces macrophage oxidative state, whereas white grape juice sugar fraction increases it.
TL;DR: PJ sugar fraction, unlike WGJ sugar fractions, decreases macrophage oxidative state under normal and under diabetic conditions, which could be due to the presence of unique complex sugars and/or phenolic sugars in PJ.
Journal ArticleDOI
Plasma LDL Oxidation Leads to Its Aggregation in the Atherosclerotic Apolipoprotein E-Deficient Mice
TL;DR: It is concluded that in E degree mice, LDL oxidation, which already took place in the plasma, can lead to the lipoprotein aggregation, and the use of an appropriate antioxidant can inhibit the formation of both atherogenic forms of LDL.
Journal ArticleDOI
The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β-cell insulin release.
TL;DR: PON1 is a potent anti-diabetic enzyme that exerts this protection against diabetes through its antioxidative, as well as via its insulin stimulation properties on β-cells.
Journal ArticleDOI
Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2.
Raanan Shamir,Corina Hartman,Rachel Karry,Elsa Pavlotzky,Rami Eliakim,Jesse Lachter,Alain Suissa,Michael Aviram +7 more
TL;DR: P polarized secretion of PON1 (basolateral) and PON2 (apical) into Caco-2 culture medium is shown, raising the possibility that intestine is capable of producing and releasing PON3 to the circulation, whereas PON 2 is released at the brush-border membrane to intestinal lumen where it may perform another yet unclear function.